7,8-Dihydroxyflavone.
A synthetic flavone that mimics BDNF (brain-derived neurotrophic factor), potentially supporting brain plasticity and neuroprotection. Mimics BDNF by binding to TrkB receptors, potentially enhancing brain plasticity, memory formation, and neuroprotection
Reviewed March 2026
- Category
- Compound
- Also filed under
- TrkB receptor agonist (mimics BDNF)Neuroprotective in animal modelsMay support learning and memoryCrosses blood brain barrier
What 7,8-Dihydroxyflavone is, and what it does.
- Does it work
- It suits people who follow early neuroscience closely and accept that the evidence base is animal and laboratory work. Human trials have not been run yet.
- How much to take
- 10-30mg daily is the common self-experimentation dose. This is entirely based on allometric scaling from animal studies. Nobody actually knows the optimal human dose.
- Time to feel it
- Nobody has measured a human time course for this one. The rodent learning studies dosed daily across two to four weeks before testing.
- The first dose
- There is no controlled human record of day one, so anything reported at that point is anecdote rather than measurement.
- With regular use
- Unknown in humans. In rodents, chronic administration improved learning and memory over weeks. Whether this translates to humans is pure speculation at this point.
- How well tolerated
- Human tolerance has not been studied, so no established daily amount exists. Worth a conversation with your doctor, and not one for pregnancy or breastfeeding.
- How it feels
- Anecdotal reports: vivid dreams, enhanced learning speed, improved mood. But these are from self-selected nootropic enthusiasts, not controlled trials. Take with a boulder of salt.
- The overlooked benefit
- It also blocks pyridoxal phosphatase, which shifts vitamin B6 handling. That is a separate action from the receptor work and rarely gets a mention.
10 to 50mg a day is where 7,8-Dihydroxyflavone works.
Source: Jang et al. 2010, multiple rodent studies
The proof, claim by claim.
These words describe the research, not the molecule's worth. Research strength is how much work stands behind one claim, and it is never a product score.
- Mimics BDNF and activates TrkB receptors
- Improves memory and learning
- Neuroprotective potential
Questions people ask about 7,8-Dihydroxyflavone.
- Is this actually safe to take?
- Honest answer: we don't know. No human safety trials exist. Animal studies haven't shown obvious toxicity, and the flavone structure is generally benign. But you're accepting unknown risk. This is experimental territory.
- Why are there no human trials?
- Poor oral bioavailability is the main barrier. The compound doesn't survive digestion well, making it hard to get consistent brain levels. Researchers are developing prodrug versions (R13) that might lead to actual clinical trials.
- Do the animal results mean anything for humans?
- They tell us the mechanism works in mammals. But the translation rate from animal nootropic studies to human efficacy is very low. Many compounds that make mice smarter do nothing for humans.
- What's the oral bioavailability problem?
- 7,8-DHF is rapidly metabolized by liver enzymes and may not reach the brain in sufficient concentrations when taken orally. This is why some people try sublingual administration or co-administration with enzyme inhibitors.
- Should I take this or just exercise?
- Exercise is one of the most potent natural ways to increase BDNF. It's free, well-studied, and has zero unknown risks. If you're not exercising regularly, that's a much better first step than an experimental compound.
- What about the R13 prodrug version?
- R13 is a modified version designed to survive digestion and convert to 7,8-DHF in the brain. It shows better results in animal studies. It's not commercially available as a supplement yet but represents the next generation of this approach.
Why these belong in the same formula. Each row says what the basis is, from settled biochemistry through to a trial that measured the pair.
Pyridoxal phosphatase removes the phosphate from pyridoxal-5-phosphate, the active B6 vitamer, as part of normal B6 turnover. Inhibiting that phosphatase raises intracellular pyridoxal phosphate independently of any receptor effect. Anyone reading this compound as a purely neurotrophic agent is missing a direct action on vitamin B6 handling, and the pairing deserves to be stated rather than assumed neutral.
Supplying pyridoxal-5-phosphate directly and simultaneously inhibiting the phosphatase that clears it act on the same pool from two directions. The published work characterised the inhibition in enzyme and cell systems rather than in people, so the human consequence of the combination has not been measured. Read it as a mechanistic flag on a co-formulation, not as a dosing instruction.
7,8-Dihydroxyflavone carries a catechol group and is cleared rapidly by glucuronidation, sulfation and catechol-O-methyltransferase, which is why its oral exposure is low. Piperine inhibits the glucuronidation step that handles flavonoids of this class. The same mechanism that raises exposure also raises exposure to anything else sharing that route, which is the trade-off in the pairing.
Quercetin and 7,8-dihydroxyflavone are both flavonoids handled by UGT and sulfotransferase enzymes and by catechol-O-methyltransferase. Taken together they compete for a limited conjugation capacity, so each can slow the other's clearance. This is a pharmacokinetic interaction with no combination trial behind it in this pairing.
Luteolin is a flavone with its own catechol group on the B ring, handled by the same methylation and glucuronidation machinery. Two catechol-bearing flavonoids taken together compete for catechol-O-methyltransferase capacity. The interaction is metabolic rather than a pooling of effect.
Apigenin lacks a catechol group but is still glucuronidated and sulfated along the same route. Co-ingestion divides conjugating capacity between the two flavones. The practical effect is on exposure of each rather than on any shared target.
7,8-Dihydroxyflavone is poorly soluble in water, and dissolution is the first limit on how much is absorbed. Phospholipid complexes and lipid dispersions are the standard formulation answer for flavonoids with this problem. The mechanism is solubility and dispersion, not a change in what the molecule does once absorbed.
A lipid vehicle keeps a poorly soluble flavonoid dispersed through gastric emptying and supports micellar solubilisation in the small intestine. Medium-chain triglycerides are used for that purpose because they emulsify readily. Effect size for this specific molecule has not been measured in people.
DHA is concentrated in neuronal membrane phospholipids and its status has been linked to BDNF and TrkB signalling in preclinical work. 7,8-Dihydroxyflavone is characterised as a small-molecule TrkB agonist. The pairing is a shared-pathway argument built on preclinical evidence and remains mechanistic, not a demonstrated combination effect in people.
Curcumin is another polyphenol whose preclinical work touches BDNF signalling, and like this flavone it is heavily glucuronidated. The pairing therefore carries both a shared-pathway argument and a competition for conjugating capacity. Neither side of that has been measured in a combination study.
Hericium erinaceus compounds are discussed in preclinical work in relation to nerve growth factor rather than BDNF. 7,8-Dihydroxyflavone is characterised against the TrkB receptor. The two are grouped in products by theme rather than by a demonstrated interaction, and no combination data exists.
Bacopa's bacosides act through cholinergic and antioxidant routes described in human trials of the herb. This flavone acts on a receptor tyrosine kinase in preclinical models. Co-formulation is a market convention rather than a mechanistic pairing, and it should be labelled as such.
EGCG is a catechol-containing polyphenol and a known substrate and inhibitor of catechol-O-methyltransferase. 7,8-Dihydroxyflavone carries its own catechol and is methylated by the same enzyme. Taken together, each slows the other's methylation, raising exposure to both in a way neither product label anticipates.
Catechol groups oxidise readily to quinones in neutral aqueous solution, which is a stability problem for a dihydroxyflavone in a liquid or a wet formulation. Ascorbate holds the reduced state and is used with catechol-bearing compounds for that reason. The mechanism is formulation stability rather than an effect in the body.
Talk to a doctor before taking 7,8-Dihydroxyflavone if any of these apply to you: No human clinical trials, Optimal human dose unknown, Long-term safety not established, Most data from rodent studies. These are flags to check first, not effects 7,8-Dihydroxyflavone is known to cause.
Not medical advice. Show the label to your pharmacist.What 7,8-Dihydroxyflavone actually does.
It's a flavone carrying two hydroxyl groups side by side, at the 7 and 8 spots on one of its rings. Two hydroxyls on neighbouring carbons is what chemists call a catechol, and that shape drives most of its chemistry.
That catechol is an easy target. Enzymes methylate it, the body tags it and clears it quickly, and it oxidises on its own in water. So the amount reaching your bloodstream is small next to the dose you swallow.
Gut wall and liver enzymes attach sugar and sulfate groups to flavones like this one. The bottleneck on blood levels is that first pass through, not whether the powder dissolves.
Two hydroxyls sitting next to each other on a ring grab hold of metals like iron and copper. A catechol flavone can bind them and change how they behave in solution.
Where 7,8-Dihydroxyflavone comes from.
This one is built in a lab from chemical starting materials, not pulled out of a plant, even though flavones like it occur in plants in tiny amounts. The tricky part of the manufacturing is making sure the two hydroxyl groups end up in the right positions and that near-identical variants are separated out. Ask a supplier for the purity certificate, because that is where the difference shows up.
Chemically synthesised. The molecule is identical to the one a plant or an animal makes, and building it deliberately means a known purity, a fixed dose and no crop contaminants. For several nutrients this is the only route that reaches a usable amount.
Synthesis starts from a polyhydroxylated acetophenone bearing the future 7 and 8 oxygen positions, together with a benzoyl donor supplying the B ring.
Standard flavone chemistry is used, typically a Baker-Venkataraman rearrangement or an Algar-Flynn-Oyamada route, to form the chromone core, with the catechol hydroxyls protected during the ring-forming step and freed afterwards.
The crude product is purified by recrystallisation and, where needed, column chromatography to remove positional isomers such as the 6,7- and 3',4'-dihydroxy analogues, which are chemically similar and easy to carry through.
Structure is confirmed by nuclear magnetic resonance and mass spectrometry, with purity set by high performance liquid chromatography and residual solvent limits from the synthetic steps.
Supplied as the dry powder or complexed with cyclodextrin or phospholipid, packed under conditions that limit oxygen and moisture contact with the catechol group.
Getting 7,8-Dihydroxyflavone from food.
The whole-food sources on file. A supplement closes the gap, it does not replace dinner.
A gram-for-gram figure (how much of each you would eat to match a dose) will appear here once it is sourced and reviewed. This page will not print a number it cannot cite.
The forms it comes in.
The essence, in one line each.
- 7,8-Dihydroxyflavone directly inhibited human and murine pyridoxal phosphatase, raising cellular pyridoxal-5-phosphate, which the authors describe as an activity independent of TrkB.In vitro study. Brenner et al., 2024 (eLife). PMID 38856179 ↗
- Oral dosing was reported to support retinal ganglion cell survival in a preclinical model, with accompanying changes in gut microbial composition and in markers of iron-dependent cell death.Animal study. Zhou et al., 2025 (CNS Neuroscience and Therapeutics). PMID 40365730 ↗
- BDNF-TrkB signalling was reported to support alveolar type 2 epithelial cell survival in a neonatal lung model, with 7,8-dihydroxyflavone named as a TrkB-directed tool compound. The study is about the pathway rather than about the supplement.Animal study. Kuiper-Makris et al., 2025 (American Journal of Respiratory Cell and Molecular Biology). PMID 40198801 ↗
- 7,8-Dihydroxyflavone appeared as one metabolite feature among many in the plasma metabolomic profiles of grazing cattle given tannin supplementation. This is a detected metabolite association, not an administered dose.Animal study. Muzzo et al., 2026 (Journal of Animal Science). PMID 42289986 ↗
These are the studies our verdict leans on, chosen from the 4 we read for 7,8-Dihydroxyflavone. The full linked list is below.
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This information is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Consult your healthcare provider before starting any supplement regimen.
